Ibrutinib

Identification

Name

Ibrutinib

Accession Number

DB09053

Description

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and it presents a very promising activity in B cell malignancies.⁴ Ibrutinib was developed by Pharmacyclics Inc and in November 2013 was FDA-approved for the treatment of mantle cell lymphoma. Later, in February 2014, ibrutinib was approved for the treatment of chronic lymphocytic leukemia and it is also indicated for the treatment of patients with Waldenström's Macroglobulinemia.¹³ Ibrutinib has also been approved by the EMA for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.⁴ Ibrutinib was approved for use in chronic graft versus host disease in August 2017 ¹².

Type

Small Molecule

Groups

Approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Ibrutinib (DB09053)

×

Close

Weight

Average: 440.507
Monoisotopic: 440.196074037

Chemical Formula

C₂₅H₂₄N₆O₂

Synonyms

• 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
• Ibrutinib

External IDs

• CRA-032765
• PC-32765
• PCI 32765
• PCI-32765
• PCI-32765-00

Pharmacology

Indication

Ibrutinib acquired an accelerated approval for the treatment of mantle cell lymphoma who have received at least one prior therapy.^Label Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma that develops in the outer edge of a lymph node. MCL is usually diagnosed at late stages and it is easily spread into bone marrow, spleen, liver and gastrointestinal tract.¹⁴

Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) who have at least one prior therapy.^Label CLL is a type of cancer caused by an overproduction of lymphocytes by the bone marrow. Some of the symptoms include swollen lymph nodes and tiredness.¹⁵

Ibrutinib is indicated for the treatment of chronic lymphocytic leukemia (CLL) with 17p deletion.^Label CLL with 17p is a type of leukemia in which a deletion in 17p disrupts the tumor suppressor p53 by deleting one allele of the TP53 gene. The remaining allele is mainly inactivated and thus, this type of leukemia is unresponsive to p53-dependent treatments.⁵

Ibrutinib is indicated for the treatment of patients with Waldenstrom's Macroglobulinemia (WM).^Label WM, also called lymphoplasmacytic lymphoma, is a type of non-Hodgkin lymphoma in which the cancer cells make large amounts of macroglobulin. The macroglobulin is a monoclonal protein that corresponds to the type of IgM antibodies and the unrestricted formation of this protein causes typical symptoms such as excessive bleeding and effects in vision and nervous system.¹⁶

Associated Conditions

• Chronic Lymphocytic Leukaemia (CLL)
• Mantle Cell Lymphoma (MCL)
• Waldenström's Macroglobulinemia (WM)

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

In vitro studies have shown an induction of CLL cell apoptosis even in presence of prosurvival factors. It has also been reported an inhibition of CLL cell survival and proliferation as well as an impaired in cell migration and a reduction in the secretion of chemokines such as CCL3 and CCL4. The latter effect has been shown to produce regression in xenograft mouse models.⁶

Clinical studies for relapsed/refractory CLL in phase I and II showed an approximate 71% of overall response rate.^7,8. In the case of relapsed/refractory mantle cell lymphoma, approximately 70% of the tested patients presented a partial or complete response.^7,9. In clinical trials for relapsed/refractory diffuse large B-cell lymphoma, a partial response was found in between 15-20% of the patients studied; while for patients with relapsed/refractory Waldenstrom's macroglobulinemia, a partial response was observed in over 75% of the patients tested. Finally, for patients with relapsed/refractory follicular lymphoma, a partial to complete response was obtained in approximately 54% of the patients.⁷

Mechanism of action

Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ.⁶

Target	Actions	Organism
ATyrosine-protein kinase BTK	inhibitor	Humans

Absorption

Ibrutinib is rapidly absorbed after oral administration and it presents a Cmax, tmax and AUC of approximately 35 ng/ml, 1-2 hour and 953 mg.h/ml respectively.¹¹

Volume of distribution

The volume of distribution at steady-state of ibrutinib is in approximately 10,000 L.¹¹

Protein binding

Irreversible plasma protein binding increases gradually over time and reaches 25% of the administered dose 8 hours after initial administration. From the plasma proteins, ibrutinib has been shown to be mainly bound to albumin and to bind to α1 AGP.³ The irreversible protein binding of ibrutinib to plasma proteins can account for 97.3% of the administered dose.¹¹

Metabolism

Three metabolic pathways have been identified according to the possible metabolites. These pathways are the hydroxylation of the phenyl group (M35), the opening of the piperidine with a reduction of the primary alcohol (M34) and the oxidation to a carboxylic acid and epoxidation of the ethylene followed by a hydrolysis to the formation of dihydrodiol (PCI-45227). The latter metabolite presents also 15 times lower inhibitory activity against BTK. The metabolism of ibrutinib is mainly performed by CYP3A5 and CYP3A4. and in a minor extent it is seen to be performed by CYP2D6.³

Hover over products below to view reaction partners

• Ibrutinib
  • PCI-7503 (M23)
  • PCI-48303 (M26)
  • PCI-45227 (M37)
  • PCI-45773 (M35)
    • M17
  • PCI-45741 (M25)
    • M20
  • PCI-45752 (M34)
    • M17
    • M24

Route of elimination

The cumulative excretion of ibrutinib in urine is of about 7.8% of the administered dose and most of this excretion is found during the first 24 hours after administration. In feces, the cumulative excretion accounts for 80% of the administered dose and the excretion occurs within 48 hours of the initial administration. The total excretion of ibrutinib during the first 168 hours after initial administration accounts for 88.5% of the administered dose.³

Half-life

The elimination half-life of ibrutinib is of approximately 4-6 hours.¹¹

Clearance

In patients with normal renal function, the clearance rate is in the range of 112-159 ml/min.³

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Ibrutinib was not showed to present a mutagenic potential in bacterial assays, nor clastogenic in chromosome aberration assays in mammalian cells or in bone marrow micronucleus assays in mice. Carcinogenicity or effects on fertility have not been determined.^Label

Affected organisms

• Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Abaloparatide	The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Ibrutinib.
Abametapir	The serum concentration of Ibrutinib can be increased when it is combined with Abametapir.
Abatacept	The metabolism of Ibrutinib can be increased when combined with Abatacept.
Abciximab	The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Abciximab.
Abiraterone	The metabolism of Ibrutinib can be decreased when combined with Abiraterone.
Acalabrutinib	The metabolism of Ibrutinib can be decreased when combined with Acalabrutinib.
Acebutolol	The metabolism of Ibrutinib can be decreased when combined with Acebutolol.
Acenocoumarol	The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Acenocoumarol.
Acetaminophen	The metabolism of Ibrutinib can be decreased when combined with Acetaminophen.
Acetazolamide	The metabolism of Ibrutinib can be decreased when combined with Acetazolamide.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

• Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of ibrutinib.
• Avoid St. John's Wort. This herb induces CYP3A4 and may reduce the serum concentration of ibrutinib.
• Take at the same time every day.
• Take with a full glass of water.

Products

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Imbruvica	Capsule	140 mg	Oral	Janssen Cilag International Nv	2014-10-21	Not applicable
Imbruvica	Tablet, film coated	420 mg/1	Oral	Pharmacyclics LLC	2018-02-16	Not applicable
Imbruvica	Tablet	420 mg	Oral	Janssen Pharmaceuticals	Not applicable	Not applicable
Imbruvica	Capsule	70 mg/1	Oral	Pharmacyclics LLC	2017-12-20	Not applicable
Imbruvica	Capsule	140 mg	Oral	Janssen Pharmaceuticals	2014-11-19	Not applicable
Imbruvica	Capsule	140 mg	Oral	Janssen Cilag International Nv	2014-10-21	Not applicable
Imbruvica	Tablet, film coated	280 mg/1	Oral	Pharmacyclics LLC	2018-02-16	Not applicable
Imbruvica	Tablet	280 mg	Oral	Janssen Pharmaceuticals	Not applicable	Not applicable
Imbruvica	Capsule	140 mg/1	Oral	Pharmacyclics LLC	2013-11-13	Not applicable
Imbruvica	Tablet, film coated	560 mg/1	Oral	Pharmacyclics LLC	2018-02-16	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Categories

ATC Codes

L01XE27 — Ibrutinib

• L01XE — Protein kinase inhibitors
• L01X — OTHER ANTINEOPLASTIC AGENTS
• L01 — ANTINEOPLASTIC AGENTS
• L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Categories

• Antineoplastic Agents
• Antineoplastic and Immunomodulating Agents
• Cytochrome P-450 CYP2D6 Substrates
• Cytochrome P-450 CYP3A Substrates
• Cytochrome P-450 CYP3A4 Substrates
• Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
• Cytochrome P-450 CYP3A5 Substrates
• Cytochrome P-450 Substrates
• Immunosuppressive Agents
• Kinase Inhibitor
• Myelosuppressive Agents
• Narrow Therapeutic Index Drugs
• Protein Kinase Inhibitors
• Tyrosine Kinase Inhibitors

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Diphenylethers

Direct Parent

Diphenylethers

Alternative Parents

Diarylethers / Phenylpyrazoles / Pyrazolo[3,4-d]pyrimidines / N-acylpiperidines / Phenol ethers / Phenoxy compounds / Aminopyrimidines and derivatives / Imidolactams / Heteroaromatic compounds / Tertiary carboxylic acid amides / Acrylic acids and derivatives / Amino acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic oxides / Primary amines / Hydrocarbon derivatives / Carbonyl compounds

show 8 more

Substituents

Acrylic acid or derivatives / Amine / Amino acid or derivatives / Aminopyrimidine / Aromatic heteropolycyclic compound / Azacycle / Azole / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Diaryl ether / Diphenylether / Ether / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam / N-acyl-piperidine / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organoheterocyclic compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Phenol ether / Phenoxy compound / Phenylpyrazole / Piperidine / Primary amine / Pyrazole / Pyrazolo[3,4-d]pyrimidine / Pyrazolopyrimidine / Pyrimidine / Tertiary carboxylic acid amide

show 24 more

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

aromatic ether, N-acylpiperidine, aromatic amine, pyrazolopyrimidine, acrylamides (CHEBI:76612)

Chemical Identifiers

UNII

1X70OSD4VX

CAS number

936563-96-1

InChI Key

XYFPWWZEPKGCCK-GOSISDBHSA-N

InChI

InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1

IUPAC Name

1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one

SMILES

NC1=NC=NC2=C1C(=NN2[[email protected]@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1

References

General References

1. Bagcchi S: Ibrutinib in pretreated Waldenstrom's macroglobulinaemia. Lancet Oncol. 2015 May;16(5):e204. doi: 10.1016/S1470-2045(15)70185-3. Epub 2015 Apr 16. [PubMed:25892147]
2. Kim ES, Dhillon S: Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia. Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. [PubMed:25802231]
3. Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, Mannens G: Absorption, metabolism, and excretion of oral (1)(4)C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97. doi: 10.1124/dmd.114.060061. Epub 2014 Dec 8. [PubMed:25488930]
4. Berglof A, Hamasy A, Meinke S, Palma M, Krstic A, Mansson R, Kimby E, Osterborg A, Smith CI: Targets for Ibrutinib Beyond B Cell Malignancies. Scand J Immunol. 2015 Sep;82(3):208-17. doi: 10.1111/sji.12333. [PubMed:26111359]
5. Sellner L, Denzinger S, Dietrich S, Glimm H, Merkel O, Dreger P, Zenz T: What do we do with chronic lymphocytic leukemia with 17p deletion? Curr Hematol Malig Rep. 2013 Mar;8(1):81-90. doi: 10.1007/s11899-012-0143-0. [PubMed:23188619]
6. Davids MS, Brown JR: Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase. Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. [PubMed:24941982]
7. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013 Jan 1;31(1):88-94. doi: 10.1200/JCO.2012.42.7906. Epub 2012 Oct 8. [PubMed:23045577]
8. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S: Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. [PubMed:23782158]
9. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19. [PubMed:23782157]
10. Authors unspecified: Ibrutinib. Aust Prescr. 2015 Oct;38(5):178-80. Epub 2015 Jun 15. [PubMed:26648658]
11. Bronson J., Black A., Dhar M., Ellsworth B. and Merritt R. (2014). Annual reports in medicinal chemistry. Elsevier.
12. FDA: Ibrutinib cGVHD approval [Link]
13. FDA approved drugs [Link]
14. Canadian cancer society [Link]
15. National Cancer Institute [Link]
16. American Cancer Society [Link]

External Links

KEGG Drug

D10223

PubChem Compound

24821094

PubChem Substance

310264995

ChemSpider

26637187

BindingDB

50357312

RxNav

1442981

ChEBI

76612

ChEMBL

CHEMBL1873475

ZINC

ZINC000035328014

PharmGKB

PA166121346

PDBe Ligand

1E8

Drugs.com

Drugs.com Drug Page

Wikipedia

Ibrutinib

AHFS Codes

• 10:00.00 — Antineoplastic Agents

PDB Entries

4ifg / 4rz7 / 5p9i / 5yu9 / 6yg2 / 6yz4

FDA label

Download (579 KB)

MSDS

Download (24.9 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Enrolling by Invitation	Treatment	Graft Versus Host Disease (GVHD) / Leukemia, B-Cell / Lymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL) / Tumors, Solid	1
4	Recruiting	Other	Leukemia, Lymphocytic, Chronic, B-Cell / Mantle Cell Lymphoma (MCL)	1
4	Recruiting	Treatment	Waldenström's Macroglobulinemia (WM)	1
3	Active Not Recruiting	Treatment	Anemia / Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma	1
3	Active Not Recruiting	Treatment	Chronic Graft Versus Host Disease	1
3	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL)	4
3	Active Not Recruiting	Treatment	Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma	1
3	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD)	1
3	Active Not Recruiting	Treatment	Graft Versus Host Disease (GVHD) / Graft-versus-host Disease (GVHD)	1
3	Active Not Recruiting	Treatment	Leukemia, Lymphocytic, Chronic, B-Cell	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Capsule	Oral	140 mg/1
Capsule	Oral	140 mg
Capsule	Oral	70 mg/1
Tablet	Oral	140 mg
Tablet	Oral	280 mg
Tablet	Oral	420 mg
Tablet	Oral	560 mg
Tablet, film coated	Oral	140 MG
Tablet, film coated	Oral	140 mg/1
Tablet, film coated	Oral	280 MG
Tablet, film coated	Oral	280 mg/1
Tablet, film coated	Oral	420 MG
Tablet, film coated	Oral	420 mg/1
Tablet, film coated	Oral	560 MG
Tablet, film coated	Oral	560 mg/1
Capsule		140 mg
Capsule	Oral
Capsule, coated	Oral	140 mg

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
Unlock Additional Data
US8476284	No	2013-07-02	2026-12-28
US8703780	No	2014-04-22	2026-12-28
US8754090	No	2014-06-17	2031-06-03
US8497277	No	2013-07-30	2026-12-28
US9125889	No	2015-09-08	2031-06-03
US8999999	No	2015-04-07	2031-06-03
US8697711	No	2014-04-15	2026-12-28
US8754091	No	2014-06-17	2026-12-28
US9181257	No	2015-11-10	2026-12-28
US8957079	No	2015-02-17	2026-12-28
US8008309	No	2011-08-30	2026-12-28
US8735403	No	2014-05-27	2026-12-28
US9296753	No	2016-03-29	2033-10-30
US7514444	No	2009-04-07	2026-12-28
US9540382	No	2017-01-10	2033-08-18
US8952015	No	2015-02-10	2026-12-28
US9725455	No	2017-08-08	2033-06-03
US9713617	No	2017-07-25	2033-06-03
US9795604	No	2017-10-24	2034-10-24
US9801883	No	2017-10-31	2031-06-03
US9801881	No	2017-10-31	2031-06-03
US9814721	No	2017-11-14	2031-06-03
US8563563	No	2013-10-22	2027-04-26
US9655857	No	2017-05-23	2036-03-03
US10004746	No	2018-06-26	2031-06-03
US10016435	No	2018-07-10	2031-06-03
US10010507	No	2018-07-03	2036-03-03
US10106548	No	2018-10-23	2033-06-03
US10125140	No	2018-11-13	2033-06-03
US10213386	No	2019-02-26	2036-03-03
US10294232	No	2019-05-21	2033-06-03
US10294231	No	2019-05-21	2033-06-03
US10463668	No	2019-11-05	2034-10-24
US10478439	No	2019-11-19	2031-06-03
US10653696	No	2011-06-03	2031-06-03
US10695350	No	2014-10-24	2034-10-24

Additional Data Available

Filed On
Filed On
The date on which a patent was filed with the relevant government.
Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	149-158ºC	FDA Imbruvica review. (2013)
water solubility	0.003 mg/ml	FDA Imbruvica review. (2013)
logP	3.97	FDA Imbruvica review. (2013)
pKa	3.74	FDA Imbruvica review. (2013)

Predicted Properties

Property	Value	Source
Water Solubility	0.0203 mg/mL	ALOGPS
logP	2.76	ALOGPS
logP	3.63	ChemAxon
logS	-4.3	ALOGPS
pKa (Strongest Acidic)	19.7	ChemAxon
pKa (Strongest Basic)	6.58	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	99.16 Å2	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	138.07 m3·mol-1	ChemAxon
Polarizability	47.84 Å3	ChemAxon
Number of Rings	5	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on May 07, 2015 13:33 / Updated on October 27, 2020 11:13